Track topics on Twitter Track topics that are important to you
After more than four years of testing and vaccinations under compassionate use protocols, the most effective Ebola vaccine has at last received World Health Organization (WHO) pre-qualification, clearing regulatory hurdles for its wide-scale use.
“AHF has been calling for an approved vaccine for more than a year—even before the current outbreak in the DRC (Democratic Republic of the Congo) began last August. We’re glad the WHO has finally pre-qualified it—unfortunately, this is bittersweet because it has taken entirely too long given the devastation that Ebola brings and the clear evidence of the vaccine’s efficacy,” said AHF President Michael Weinstein. “Now we urge the US FDA [Food and Drug Administration] to also approve the vaccine so that sufficient quantities can be produced and stockpiled—especially in areas where outbreaks are more likely to occur so they can be accessed quickly when needed.”
The success of the first trial for the Merck Ebola vaccine, rVSV-ZEBOV, was first reported in the Lancet in July 2015. Since then, it has shown to be over 97% effective and fast-acting, with immunity just 10 days after an individual is vaccinated.
The WHO pre-qualification comes on the heels of vaccine’s approval by the European Commission, which makes it the first officially approved Ebola vaccine in the world.
“Whether it’s the ongoing outbreak in the DRC or the next Ebola hotspot in the future—we have definitely not seen the end of this virus,” added Weinstein. “If this approval process has taught us anything, it’s that we’re not prepared for infectious disease outbreaks of this magnitude. We urge the global public health community to seize this opportunity and reevaluate the inadequate practices and procedures that, ultimately, put the entire world at risk with unnecessary delays and runaway bureaucracy.”
Even though the current outbreak in the DRC is showing early signs of slowing, contact tracing and containment is now more difficult since the virus has moved to less populated, rural areas and violence and insecurity continues throughout the affected region.
As of November 13, nearly 3,300 Ebola cases in the DRC have resulted in 2,192 deaths.
For more information, please contact Ged Kenslea at firstname.lastname@example.org or (323) 791-5526
About AIDS Healthcare Foundation (AHF)
AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.2 million people in 43 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare.
U.S. MEDIA CONTACTS:
Ged Kenslea, Senior Director, Communications, AHF
+1 323 308 1833 work +1.323.791.5526 mobile
Denys Nazarov, Director of Global Policy &
Marburg and Ebola Virus Infections
Ebola virus and Marburg virus are related viruses that cause hemorrhagic fevers — illnesses marked by severe bleeding (hemorrhage), organ failure and, in many cases, death. Both viruses are native to Africa, where sporadic outbreaks have occurred f...
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...
Tropical Medicine is the study of diseases more commonly found in tropical regions than elsewhere. Examples of these diseases are malaria, yellow fever, Chagas disease, Dengue, Helminths, African trypanosomiasis, Leishmaniasis, Leprosy, Lymphatic filaria...